CP is a multifactorial disease, and relations between CP and systemic diseases have gathered increasing attention. The association between CP and LBW was first reported by Offenbacher et al. [1]. Many epidemiological studies have reported that pregnant women with CP are several times more likely than women without CP to have a preterm LBW infant [5–22]. Additionally, some studies have found that treatment for periodontitis is effective for preventing LBW [45–48]. Those studies reported that CP was an important risk factor for LBW. Specifically, hormonal alterations during pregnancy can cause bacterial infections to progress into periodontitis [2–4, 49]. Chronic inflammation with CP induces the production of some proinflammatory cytokines [50–52]. Moreover, molecular studies have reported increased placental expression of interleukin-1 beta (IL-1 beta), cyclooxygenase-2 (COX-2), vascular endothelial growth factor receptor (VEGFR1), and heat shock protein (HSP70) in patients with CP [53]. These inflammatory mediators cause uterine contraction and vasoconstriction, which lead to LBW [54].
However, conversely, some studies have reported finding no association between CP and preterm LBW, and that treatment for periodontitis had no effect on the prevention of LBW [55–66]. Furthermore, as LBW is related to numerous risk factors, such as the mother’s age, onset of prenatal care, systemic diseases, previous LBW infants, complications during pregnancy, and term of delivery, CP may not be an important risk factor for LBW [23–27, 67]. Thus, the precise association between CP and LBW remains unclear.
In this study, we focused on common genetic factors and molecular interactions between CP and LBW by performing gene expression analyses with pooled datasets from the GEO database.
Microarray analysis is a powerful tool to identify new candidate genes involved in the gene expression profiling of multifactorial diseases. Gene expression profiling involves the comprehensive study of gene expression levels; these can be used to diagnose a disease or predict treatment effects. The NCBI GEO database is the largest public repository for high-throughput biological assays generated by the research community [35–44].
In addition, data sharing and the integration of pooled omics data for investigations of biomedical mechanisms and multifactorial disease relations have gained increasing attention. Using pooled microarray gene expression datasets from the GEO is a method that reduces high-throughput hybridization costs and compensates for insufficient amounts of mRNA sampling [32–34].
In this study, we analyzed microarray gene expression datasets from the GEO database to elucidate the association between CP and preterm LBW. Although the two datasets contain different experiment conditions, subjects, and diseases, the relation between common genetic factor and biological interaction candidates and multifactorial diseases such as CP and LBW may be elucidated as screening tools.
Common genetic factors, molecular pathways, genetic interactions, and biomarker candidates between CP and LBW were analyzed using DAVID, STRING, and IPA. DAVID is a web-accessible program that provides a comprehensive set of functional annotation tools for investigators to understand biological meanings behind large lists of given genes [68]. STRIG is a database of known and predicted PPIs of multiple proteins [69]. IPA is an application built on a large knowledge database acquired by curators. IPA is a powerful application for the discovery of upstream regulators and biomarker candidates with omics data such as microarray analysis that identifies new biomarkers within the context of biological systems [70, 71].
The aim of this study was to elucidate key genes and biological interactions between CP and LBW using bioinformatics analysis of microarray datasets in the GEO database.
We examined important common factors and their functions related to CP and LBW. The functions of the genes were considered while referring to the information in NCBI GEO database [72].
Our analysis of CP and LBW gene expression profiles identified three significantly upregulated DEGs and 20 significantly downregulated DEGs. The three upregulated DEGs had no significant relation with each other. Among the three upregulated DEGs, PRRC2A can be assumed to be associated with inflammation and immunity as it is localized in the vicinity of the genes for tumor necrosis factors alpha and beta [72] PRRC2A is associated with rheumatoid arthritis and the age at onset of insulin-dependent diabetes mellitus [72]. Some downregulated DEGs, such as CCNB2, CDKN1C, CENPA, CEP76, NEK2, TOP2A, and TTK, were found to be related to the cell cycle from the functional analysis of the BP and pathway databases. Based on the PPI networks, TOP2 had direct interactions with the downregulated DEGs: CCNB2, TTK, NEK2, and CENPA.
The results of the IPA biomarker analysis showed that interferon-induced protein with tetratricopeptide repeats 2 (IFIT2), TOP2A, activating transcription factor 6 (ATF6), TNF superfamily member 10 (TNFSF10), NCAM1, CACNA2D3, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase (GART), PRRC2A, and Pvt1 oncogene (PVT1) were common molecular biomarker candidates.
Based on the upstream regulator analysis, catenin beta 1 (CTNNB1) and interleukin-5 (IL-5) were found to be the upstream regulators suppressing PPRC2A, which is one of the upregulated DEGs. CTNNB1 is involved in the bonding of cell adhesion molecules, the homeostasis of living organisms, and intracellular messenger activity [72]. IL-5 is a hematopoietic cytokine that plays an important role in the differentiation, maturation, mobilization, and activation of neutrophils [72].
TOP2A, NCAM1, and CACNA2D3 were identified as common downregulated DEGs, while beta-estradiol, transforming growth factor beta 1 (TGFB1), trichostatin A, and decitabine were identified as common upstream regulators showing inhibitory reactions to TOP2A and NCAM1. Sirolimus was found to be an upstream regulator showing active reactions to TOP2A and NCAM1.
As for CACNA2D3, there is nothing in common upstream regulators with TOP2A and NCAM1. Adenylate denylate-cyclase activating polypeptide 1 (ADCYAP1), musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB), achaete-scute homolog 1 (ASCL1), nuclear receptor subfamily 3 group C member 2 (NR3C2), and pancreas transcription factor 1 subunit alpha (PTF1A) were found to be active upstream regulators of CACNA2D3. ADCYAP1 is a transduction material, MAFB is involved in the differentiation of hematopoietic stem cells to monocytes and macrophages, ASCL1 is a transcription factor required when cells differentiate into neurons involved in the nuclear receptor of steroids, such as NR3C2 [72].
The results of this study revealed that PRRC2A, TOP2A, NCAM1, CACNA2D3, CTNNB1, IL5, ASCL1, NR3C2, ADCYAP1, and MAFB are genes commonly associated with CP and LBW, and that upstream regulators such as lipopolysaccharide and pregnancy-associated hormones are dominant regulators commonly associated with CP and LBW. These key genes and regulators are related to not only inflammation and immunity, but also the cell cycle, the bonding of cell adhesion molecules, intercellular messenger activity, the homeostasis of living organisms, and cell differentiation.
Previously reported genes and regulators related to both CP and LBW in the PubMed database are shown in Table 9. In this study, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) and cyclin dependent kinase inhibitor 1A (CDKN1A) were found to be activated upstream regulators of TOP2A. Beta-estradiol, CD24, erb-b2 receptor tyrosine kinase 2 (ERBB2), estrogen, lipopolysaccharide, peroxisome proliferator-activated receptor alpha (PPARA), TGFB1, and tretinoin are inhibited upstream regulators of TOP2A, while beta-estradiol, TGFB1, and tretinoin are common inhibited upstream regulators of TOP2A and NCAM1, and NCAM1 is a common downregulated DEG and biomarker. Many of the listed genes and regulators are related to cell generation, development, and organization. Some genes and regulators were found to be indirectly related to immunology and inflammation, while some hormones related to pregnancy and fetal growth were found to influence CP and LBW as upstream regulators. The pooled omics data microarray analysis carried out in this study revealed that several genes related to CP and LBW have functions relevant to cell morphology, organ morphology, and skeletal and muscular diseases, in addition to inflammation and immunity.
Table 8
Upstream regulators of dominant common biomarker candidates
Table 8. Upstream regulators of dominant common biomarker candidates
|
|
Target gene (up- or downregulated DEG)
|
Upstream regulator
|
Predicted activation state
|
PRRC2A (upregulated DEGs)
|
CTNNB1, IL5
|
Inhibited
|
TOP2A (downregulated DEG)
|
dexamethasone, TGFB1, beta-estradiol, estrogen, trichostatin A, diethylstilbestrol, IL6, FGF2, NRG1, OSM, testosterone, MYOD1, RABL6, YAP1, E2F1, P38 MAPK, poly rI:rc-RNA, lipopolysaccharide, BRD4, NR1H3, PPARA, EWSR1, FOXM1, ERBB2, decitabine, CFS2, CD3, tretinoin, LLLGL2, CD24, ELAVL1, NSUN6, trans-hydroxytamoxifen, raloxifene
|
Inhibited
|
|
LY294002, mir-21, PD98059, TCF3, dexamethasone, sirolimus, CDKN1A, BNIP3L, JQ1, KRAS, curcumin, 26 s Proteasome
|
Activated
|
NCAM1 (downregulated DEG)
|
TGFB1, beta-estradiol, tretinoin, progesterone, CTNNB1, trichostatin A, EGF, MYC, IGF1, bucladesine, WNT3A, NFkB (complex), JUN, BMP7, phytohemagglutinin, BMP4, OTX2, BDNF, CD38, NEUROD1, PAX8, EPHB4, decitabine, SOX4, CUX1, TNF, Ngf, monocrotaline
|
Inhibited
|
|
MYCN, sirolimus, NOG, miR-182-5p, KRAS, curcumin, mir-210
|
Activated
|
|
CACNA2D3 (downregulated DEG)
|
ADCYAP1, MAFB, ASCL1, NR3C2, PTF1A
|
Inhibited
|
|
Table 9
Genes and regulators reported to be related to both CP and LBW (PubMed)
Genes and regulators reported in previous studies
|
Relation in this study
|
Beta-estradiol
|
Inhibits upstream regulators of TOP2A and NCAM1
|
BNIP3L
|
Activates upstream regulator of TOP2A
|
Camptothecin
|
|
CD24
|
Inhibits upstream regulator of TOP2A
|
CDKN1A
|
Activates upstream regulator of TOP2A
|
Cisplatin
|
|
CYP3A4
|
|
Doxorubicin
|
|
ERBB2
|
Inhibits upstream regulator of TOP2A
|
ESR1
|
|
Estrogen
|
Inhibits upstream regulator of TOP2A
|
FAS
|
|
GNAS
|
|
HFE
|
|
L-dopa
|
|
Lipopolysaccharide
|
Inhibits upstream regulator of TOP2A
|
MDM2
|
|
mir-21
|
Activates upstream regulator of TOP2A
|
MTHFR
|
|
NCAM1
|
Common downregulated gene, common biomarker
|
PPARA
|
Inhibits upstream regulator of TOP2A
|
Rb
|
|
Sos
|
|
TGFB1
|
Inhibits upstream regulators of TOP2A and NCAM1
|
TP53
|
|
Tretinoin
|
Inhibits upstream regulators of TOP2A and NCAM1
|
YY1
|
|